<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04159181</url>
  </required_header>
  <id_info>
    <org_study_id>CBC-COLON-18</org_study_id>
    <nct_id>NCT04159181</nct_id>
  </id_info>
  <brief_title>The Endocrine Colon in Humans</brief_title>
  <acronym>Colon</acronym>
  <official_title>Investigations of the Endocrine Colon in Healthy Individuals</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Copenhagen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hvidovre University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Copenhagen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will examine the role of the colon as an endocrine organ with a focus on the
      secretion of gastrointestinal peptides.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will examine the role of the colon as an endocrine organ with a focus on the
      secretion of gastrointestinal peptides.

      We aim to determine the contribution of the colon to the fasting and postprandial release of
      gut peptides such as glucagon-like peptide-1 (GLP-1) and peptide YY (PYY). Young healthy men
      will be examined on three occasions at a clinical research Facility after an overnight fast.
      On one occasion the colon will also be emptied using a cathartic (picoprep). On two occasions
      an oral solution of lactulose will be administered to stimulate fermentation by colonic
      bacteria.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">July 16, 2018</start_date>
  <completion_date type="Anticipated">July 1, 2020</completion_date>
  <primary_completion_date type="Actual">July 31, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Healthy men studied on three occasions. Study A and B will be conducted in random order. Day C wil always be conducted as the last study day.</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>GLP-1</measure>
    <time_frame>-60, -45, -30, -15, 0, 15, 30, 45, 60, 75, 90, 105, 120, 135, 150, 165, 180, 195, 210, 225, 240, 255, 270. 285, 300 min</time_frame>
    <description>Plasma concentrations of glucagon-like peptide-1 (GLP-1)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PYY</measure>
    <time_frame>-60, -45, -30, -15, 0, 15, 30, 45, 60, 75, 90, 105, 120, 135, 150, 165, 180, 195, 210, 225, 240, 255, 270. 285, 300 min</time_frame>
    <description>Plasma concentrations of peptide YY (PYY)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hydrogen breath test</measure>
    <time_frame>-60, -45, -30, -15, 0, 15, 30, 45, 60, 75, 90, 105, 120, 135, 150, 165, 180, 195, 210, 225, 240, 255, 270. 285, 300 min</time_frame>
    <description>Concentrations of hydrogen in exhaled air</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ghrelin</measure>
    <time_frame>-60, -45, -30, -15, 0, 15, 30, 45, 60, 75, 90, 105, 120, 135, 150, 165, 180, 195, 210, 225, 240, 255, 270. 285, 300 min</time_frame>
    <description>Plasma concentrations of ghrelin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Motilin</measure>
    <time_frame>-60, -45, -30, -15, 0, 15, 30, 45, 60, 75, 90, 105, 120, 135, 150, 165, 180, 195, 210, 225, 240, 255, 270. 285, 300 min</time_frame>
    <description>Plasma concentrations of motilin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neurotensin</measure>
    <time_frame>-60, -45, -30, -15, 0, 15, 30, 45, 60, 75, 90, 105, 120, 135, 150, 165, 180, 195, 210, 225, 240, 255, 270. 285, 300 min</time_frame>
    <description>Plasma concentrations of Neurotensin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucagon</measure>
    <time_frame>-60, -45, -30, -15, 0, 15, 30, 45, 60, 75, 90, 105, 120, 135, 150, 165, 180, 195, 210, 225, 240, 255, 270. 285, 300 min</time_frame>
    <description>Plasma concentrations of glucagon</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Day A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>After an overnight fast participants will receive an oral solution of lactulose (20g lactulose/200mL water).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Day B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>After an overnight fast participants will drink 200mL of water</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Day C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>After an overnight fast and an evacuation of the colonic content, participants will receive an oral solution of lactulose (20g lactulose/200mL water).</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Lactulose</intervention_name>
    <description>Oral solution lactulose (20g lactulose/200mL water).</description>
    <arm_group_label>Day A</arm_group_label>
    <arm_group_label>Day C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Picoprep</intervention_name>
    <description>Cathartic to accomplish an evacuation of the colonic content.</description>
    <arm_group_label>Day C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo (water)</intervention_name>
    <description>oral administration of Water (200mL).</description>
    <arm_group_label>Day B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy young men (self-reported)

          -  BMI between 18,5-24,9 kg/m^2

        Exclusion Criteria:

          -  Diabetes mellitus (elevated fasting plasma glucose or HbA1c)

          -  Family history of diabetes mellitus

          -  Intestinal disease (e.g. inflammatory bowel disease, malabsorption)

          -  Family history of intestinal diseases

          -  Previous gastrointestinal surgery

          -  BMI &gt;25 kg/m^2

          -  Tobacco use

          -  Alcohol consumption &gt; 14 standard drinks/week

          -  Drug use

          -  Kidney, Heart- or Liver disease

          -  Treatment with prescription drugs that can not be held for 12h

          -  Constipation

          -  Accelerated or delayed gastric emptying

          -  Absence of daily bowel movements

          -  Vegetarian lifestyle

          -  &gt; than 3kgs weightloss or weight gain within 3 months

          -  Haemoglobin concentration &lt; 8,0mmol/L

          -  Bleeding diathesis

          -  Latex or bandaid allergies
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jens J Holst, MD, Dr.med.</last_name>
    <role>Study Director</role>
    <affiliation>University of Copenhagen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Copenhagen</name>
      <address>
        <city>Copenhagen</city>
        <state>Capital</state>
        <zip>2200</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hvidovre University Hospital</name>
      <address>
        <city>Hvidovre</city>
        <state>Capital</state>
        <zip>2650</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>July 9, 2018</study_first_submitted>
  <study_first_submitted_qc>November 7, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 12, 2019</study_first_posted>
  <last_update_submitted>November 7, 2019</last_update_submitted>
  <last_update_submitted_qc>November 7, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 12, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Copenhagen</investigator_affiliation>
    <investigator_full_name>Simon Veedfald</investigator_full_name>
    <investigator_title>Investigator</investigator_title>
  </responsible_party>
  <keyword>Colon</keyword>
  <keyword>PYYs</keyword>
  <keyword>GLP-1</keyword>
  <keyword>Gut peptides</keyword>
  <keyword>Fermentation</keyword>
  <keyword>Lactulose</keyword>
  <keyword>human</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lactulose</mesh_term>
    <mesh_term>Picosulfate sodium</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

